TauRx Pharmaceuticals – a company focused on Alzheimer’s disease (AD) research – has announced results from its pivotal phase 3 LUCIDITY trial.
The study measured the effect of hydromethylthionine mesylate (HMTM) on neurofilament light change (NfL) – a vital brain neurodegeneration biomarker.
Registered office
11 Lyons Walk
Shaftesbury
Dorset
SP7 8JF
office@icr-global.org